Peter V Allen
Mr Allen was appointed as Non-Executive Chairman of the Group in January 2014. He is currently the Non-Executive Chairman of AIM listed Clinigen plc and Abcam plc, together with privately owned Oxford Nanopore Technologies Limited. He is also a Non- Executive Director of Istesso Limted, and a qualified Chartered Accountant.
Mr Allen has extensive experience in the healthcare industry, having held key senior positions in a number of companies and playing a significant role in their development. This includes 12 years at Celltech Group plc (1992-2004) as CFO and Deputy CEO, six years as Chairman (2007-2013) of ProStrakan Group plc (Interim CEO 2010-11), three years as Chairman of Proximagen Neurosciences plc (2009-12), and five years as Non-Executive Chairman of Diurnal plc.
Chief Executive Officer
Mr Meredith was appointed Group Chief Executive Officer in January 2011. He joined AMS as Group Commercial Director in July 2005 following a successful 18-year career in international healthcare sales, marketing and business development. His experience prior to joining AMS covered business-to business contract manufacturing, product development and clinical research, as well as branded product sales all within the medical device, pharmaceutical or consumer healthcare markets. He was appointed Managing Director of Advanced Woundcare in February 2008 and in January 2010 he became Chief Operating Officer for the Group. Mr Meredith has previously held senior positions at Smiths Industries, Cardinal Health, Banner Pharmacaps, and Aster Cephac.
Mr Meredith was appointed as a Non-Executive Director of Creavo Medical Technologies Ltd in May 2018. Creavo Medical Technologies Ltd is a UK-based, privately-held medical device company that is developing innovative techniques.
Chief Financial Officer
Mr Johnson was appointed as Chief Financial Officer in January 2019. He joined AMS in October 2011 and was appointed Group Financial Controller in November 2012. Prior to this he gained a first class degree in Maths and Computer Science from Keele University in 1993 and qualified as a Chartered Accountant in 1996. Since moving into industry in 1996 Eddie has held a number of senior finance roles in various sectors including, more recently, Head of Commercial Finance at Norcros plc and Western European Financial Controller for Sumitomo Electrical Wiring Systems.
Senior Independent Non-Executive Director
Ms Freer was appointed as Senior Independent Non-Executive Director of AMS in March 2010. She is a partner of London Bridge Capital Partners, a corporate advisory business, Chairman of AP Ventures LLP, and a Non- Executive Director of Empresaria Group plc, Crown Place VCT plc, and The Henderson Smaller Companies Investment Trust plc.
With 25 years’ experience in investment banking she was formerly Head of Equities for Robert W Baird in London and prior to this held senior positions at Credit Lyonnais and NatWest Markets.
Mr Cook was appointed as Non-Executive Director of AMS in February 2021. He is a Non-Executive Director of Attraqt plc, Draper Espirit plc, Minoan Group plc, Pirtsemit Limited and Sapience Communications Limited and a member at T and JK Estates LLP, TJK Holdings LLP and KS Halkins LLP.
He has 18 years experience in investment banking focusing on global equity capital markets and M&A and corporate advisory. He advised the London Stock Exchange on the creation of TechMark, the specialist segment of the Main Market focusing on innovative technology and healthcare companies. He has experience in the healthcare sector, most recently as a Non-Executive Director of Morphogenesis Inc and Chairman of Sinclair Pharma plc. He has also held Board positions in a number of other companies, including Horizon Discovery plc, MDY Healthcare plc and CrawfordHEalthcare Holdings Limited.
He holds a double first degree from Oxford University and is a member of the Institute of Chartered Accountants.